Trial Profile
A MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EMICIZUMAB GIVEN EVERY 2 WEEKS AND 4 WEEKS IN HEMOPHILIA A PEDIATRIC PATIENTS AGED LESS THAN 12 YEARS WITHOUT FVIII INHIBITORS
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Emicizumab (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Acronyms HOHOEMI
- Sponsors Chugai Pharmaceutical
- 01 Nov 2021 Results assessing immunogenicity of emicizumab in seven phase 3/3b clinical studies (HAVEN 1-5, HOHOEMI and STASEY) in persons with haemophilia A, published in the Haemophilia.
- 18 Oct 2019 According to a Chugai Pharmaceutical media release, data from this study was published in Haemophilia online
- 04 Dec 2018 Results assessing efficacy and safety of emicizumab in Q2W and Q4W in patients with hemophilia patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.